Product Details
Tamoxifen + Goserelin, Oral + Implant Regimen, for Tablets BP
Product Name
:
Tamoxifen + Goserelin, Oral + Implant Regimen, for Tablets BP
Brand Name
:
VERTAM-G
Available Strength
:
-
Packing
:
28 Tablets
Pack Insert/Leaflet
:
According To Your Needs
This combined regimen meets British Pharmacopoeia standards, supporting hormone-responsive breast cancer management. Oncologists prescribe this oral-and-implant combination for premenopausal patients who need both estrogen receptor blockade and ovarian suppression.
The regimen combines:
- Tamoxifen Citrate BP (equivalent to Tamoxifen 20 mg, oral tablet) — a Selective Estrogen Receptor Modulator (SERM) that blocks estrogen receptors in breast tissue, slowing the growth of hormone-sensitive tumor cells
- Goserelin Acetate (Depot, implant regimen) — a GnRH agonist that suppresses ovarian estrogen production, achieving medical ovarian suppression when administered as a subcutaneous implant by a healthcare provider
Together, these two mechanisms complement each other. As a result, VERTAM-G supports more complete hormonal suppression than tamoxifen alone. Because Goserelin requires implant administration, oncology clinics and hospital outpatient departments typically coordinate the oral and implant components as one regimen.
Key Features
- Meets BP (British Pharmacopoeia) standards for the oral tablet component
- Pairs an oral SERM with a depot GnRH agonist for dual-mechanism hormone therapy
- Delivers accurate, validated dosing in every tablet batch
- Suits oncology clinic, hospital, and specialist institutional supply
- Follows GMP-compliant manufacturing processes
- Requires physician oversight for both the oral and implant components